Cancer Academy 2026 v1.1.2: Understand Your Cancer. Navigate the Evidence.

OneDayMD Cancer Academy

Understand Your Cancer. Navigate the Evidence.

A patient-first cancer education system designed to help you understand diagnosis, biomarkers, treatment options, treatment response, resistance, monitoring, clinical research and the questions worth asking your healthcare team.

Start With Your Journey What Should I Understand First?
Patient-first Start with the questions patients actually ask
Evidence-aware Separate established evidence from uncertainty
Clinician-compatible Designed to support better conversations
No paywall Education should remain accessible
What the Academy is

Cancer information should be a journey, not a pile of articles.

A cancer diagnosis can generate hundreds of questions: What type of cancer is this? What stage is it? Which biomarkers matter? What treatments are available? How do we know whether treatment is working? What happens if the cancer progresses?

The OneDayMD Cancer Academy organizes those questions into a connected learning pathway. Instead of treating every article as an isolated page, the Academy connects cancer type, pathology, biomarkers, treatment, response, resistance, monitoring and emerging research.

Important: The Cancer Academy is an educational resource. It does not diagnose cancer, recommend an individualized treatment plan, replace an oncologist, or provide emergency medical care.
The seven questions

The seven questions every patient should be able to explore

These seven questions form the backbone of the Cancer Academy. They are not a substitute for medical advice; they are a framework for understanding what your clinical team is evaluating.

1
What cancer do I have? Understand the cancer type, pathology, grade, stage and major features of the diagnosis.
2
How advanced is it? Learn how staging, spread, lymph-node involvement and metastatic disease influence treatment planning.
3
What does the tumor biology tell us? Explore pathology, genomic alterations, molecular markers, immune biomarkers and other clinically relevant tests.
4
What are my treatment options? Understand surgery, radiation, chemotherapy, targeted therapy, immunotherapy and other established approaches.
5
Is the treatment working? Learn how imaging, pathology, biomarkers, symptoms and clinical assessment may contribute to monitoring.
6
What happens if the cancer progresses? Understand resistance, recurrence, progression, re-biopsy, molecular reassessment and changing treatment strategies.
7
What should I ask next? Turn complex medical information into practical questions for your oncologist, surgeon, radiation oncologist or other clinician.
Patient journey

Start where you are

You do not need to read the entire Academy. Choose the stage that best matches your current question and follow the links outward.

STEP 03

Considering Treatment

Build an understanding of established treatment categories and questions to discuss with your clinical team.

Explore treatment resources →
The Academy knowledge graph

Cancer is more than a diagnosis

The Academy connects the major dimensions of modern cancer understanding rather than treating cancer type, biomarkers, treatment and resistance as separate subjects.

Stage & Extent

How large is the disease, where has it spread, and what does staging mean for clinical decision-making?

Explore cancer guides →

Biomarkers

Which molecular, genetic, protein or cellular markers may influence diagnosis, prognosis or treatment selection?

Explore biomarkers →

Resistance

Understand genetic evolution, pathway adaptation, immune escape and tumor-microenvironment mechanisms of treatment resistance.

Explore resistance →
The 10 Academy Schools

A complete cancer education system

Each School is a future content cluster. The links below connect the master pillar to the strongest existing resources in the OneDayMD network.

SCHOOL 03

Cancer Treatment

Understand the major treatment categories and how treatment decisions depend on cancer type, stage, pathology, biomarkers, patient factors and goals of care.

Treatment & cancer library →
SCHOOL 05

Targeted & Molecular Therapy

Learn how targeted therapies work, why molecular matching matters, and why cancers can evolve around targeted treatment.

Targeted therapy & biology →
Precision knowledge architecture

Cancer type × biomarker × treatment × resistance

The long-term goal of Cancer Academy is to help patients navigate cancer information across four connected dimensions. A cancer diagnosis alone rarely explains the full clinical decision.

02

Biomarkers

Molecular alterations, protein markers, immune markers, tumor burden, MSI status and other clinically relevant information.

Explore biomarkers →
03

Treatment

Surgery, radiation, systemic therapy, targeted therapy, immunotherapy and selected emerging approaches.

Explore treatment →
04

Resistance

Acquired resistance, disease progression, molecular evolution, immune escape and changes in the tumor ecosystem.

Explore resistance →
Why this matters: Two people with the same cancer type may have different pathology, stage, biomarkers, treatment histories and responses. Cancer Academy therefore treats personalization as a knowledge architecture rather than as a promise of personalized medical advice.
Evidence framework

E0–E5: making evidence strength visible

Not every cancer claim deserves the same level of confidence. Cancer Academy uses a simple evidence language to help readers distinguish established clinical knowledge from preliminary research and hypothesis.

E5 Clinical Standard

Established clinical practice supported by high-quality evidence, guidelines or broad professional consensus.

E4 Strong Clinical Evidence

Meaningful human evidence, often including randomized trials, prospective studies or strong comparative evidence.

E3 Emerging Human Evidence

Human clinical evidence exists, but evidence may be limited by study size, design, consistency or follow-up.

E2 Preclinical Evidence

Evidence primarily from laboratory, animal, mechanistic or translational research.

E1 Hypothesis / Early Signal

Interesting preliminary signals, observational findings, computational results or early hypotheses requiring validation.

E0 Insufficient Evidence

Claims lacking adequate evidence to support a meaningful clinical conclusion.

Important: An E2, E1 or E0 finding may still be scientifically interesting. It simply should not be presented to patients as equivalent to established cancer treatment evidence.
Patient tools

From information to navigation

Cancer Academy will progressively add patient-facing tools designed to help users organize information and prepare better conversations with healthcare professionals.

Roadmap

Cancer Type Explorer

Select a cancer type and navigate to the appropriate disease, biomarker, treatment and resistance resources.

Roadmap

Biomarker Navigator

Understand common biomarkers, what they measure and what questions to ask about their clinical relevance.

Roadmap

Treatment Decision Map

Educational visualization of how cancer type, stage, pathology, biomarkers and patient factors can interact with treatment choices.

Roadmap

Resistance Explorer

Explore common biological mechanisms through which cancer can become less sensitive to treatment.

Roadmap

Oncologist Question Builder

Generate a structured list of questions based on diagnosis, biomarkers, treatment and monitoring concerns.

Roadmap

Evidence Explorer

Help readers distinguish clinical standards, human evidence, preclinical findings and hypotheses.

OneDayMD Cancer Knowledge Network

One Academy. Multiple layers of knowledge.

Cancer Academy is the patient-facing master layer. The deeper OneDayMD and Cancer Advisor articles provide the research, mechanistic and disease-specific layers beneath it.

Systems-Level Cancer Control

A broad framework connecting cancer biology with metabolism, immunity, mitochondria and the tumor microenvironment.

Read the systems-level review →

Cancer Biomarker Testing Guide

A patient-oriented introduction to CEA, CA-125, PSA, CTC and related biomarker concepts.

Read the biomarker guide →

Treatment Resistance

An evidence-aware framework examining genomic, metabolic, immune and tumor-microenvironment dimensions of resistance.

Explore resistance biology →

Integrative & Precision Oncology

A hub for evidence-aware discussion of integrative cancer care, repurposed drugs and precision oncology.

Explore the research hub →

Cancer Guides & Directory

The broader Cancer Advisor library for disease-specific, treatment and emerging oncology resources.

Open the cancer library →

Oncology + Primary Care

Explore how cancer care can intersect with broader management of metabolic health, cardiovascular risk and long-term health.

Explore integrated care →
Editorial standards

How Cancer Academy content should be written

Cancer information is unusually sensitive to overstatement. Cancer Academy therefore follows a structured editorial model.

1. Separate fact from interpretation

Established clinical facts, research findings, interpretation and hypotheses should not be presented as though they have the same level of certainty.

2. Prioritize human evidence

Human clinical evidence should generally carry greater weight than cell-line, animal, mechanistic or computational findings when discussing patient care.

3. Explain limitations

Every emerging intervention should be accompanied by relevant limitations, uncertainty, safety considerations and evidence gaps.

4. Do not replace standard oncology

Experimental, complementary or integrative approaches should not be framed as substitutes for clinically appropriate cancer care.

5. Update important pages

Cancer research changes rapidly. Major clinical claims, treatment information and evidence summaries should be reviewed and updated when meaningful new evidence emerges.

6. Make uncertainty visible

Saying "we do not know yet" is an important part of trustworthy cancer communication.

Trust & E-E-A-T

Built for trustworthy cancer information

Cancer Academy aims to make its editorial process transparent: what is known, what is uncertain, where evidence comes from and when professional medical judgment is required.

Experience Patient-centered explanation and practical navigation.
Expertise Evidence synthesis across oncology, biomarkers and systems medicine.
Authority Links to peer-reviewed literature, guidelines and authoritative cancer resources where appropriate.
Trust Clear limitations, evidence grading and disclosure of uncertainty.
How to use Cancer Academy

Read vertically, then go deeper

The Academy is intentionally layered.

Layer 1 — Patient Education

Start with plain-language explanations of diagnosis, testing, treatment and monitoring.

Layer 2 — Disease & Biomarker Hubs

Move into cancer-specific and biomarker-specific resources when you know the relevant clinical details.

Layer 3 — Evidence Reviews

Read deeper research analyses when you want to understand the scientific rationale, evidence quality and controversies.

Future disease hubs

Cancer-type × biomarker × treatment hubs

The next phase of Cancer Academy will develop dedicated disease hubs. Each hub should eventually connect the same four dimensions: cancer type, biomarkers, treatment and resistance.

Lung Cancer

EGFR, ALK, KRAS, ROS1, MET, RET, PD-L1, targeted therapy, immunotherapy and resistance.

Dedicated Academy hub — planned

Breast Cancer

ER, PR, HER2, triple-negative disease, molecular classification, systemic treatment and resistance.

Dedicated Academy hub — planned

Colorectal Cancer

RAS, BRAF, MSI/MMR, HER2, targeted therapy, immunotherapy and treatment sequencing.

Dedicated Academy hub — planned

Prostate Cancer

PSA, androgen signaling, molecular testing, advanced disease and treatment resistance.

Dedicated Academy hub — planned

Pancreatic Cancer

Disease biology, staging, molecular testing, systemic therapy and emerging research.

Dedicated Academy hub — planned

Brain & Other Cancers

Disease-specific biology, biomarkers, treatment options and emerging research will be progressively added.

Dedicated Academy hubs — planned
Search & AI-ready knowledge

Designed to be understandable to both humans and AI systems

Cancer Academy uses explicit definitions, structured relationships, evidence labels, question-based headings and interconnected knowledge clusters. This makes the content easier to navigate for patients and easier for search and AI systems to interpret.

Question-led content

Pages answer the questions patients naturally ask rather than relying only on disease or drug keywords.

Entity relationships

Cancer type, biomarker, treatment, response and resistance are explicitly connected.

Evidence labels

E0–E5 provides a consistent vocabulary for communicating evidence strength across the network.

Internal knowledge graph

Academy pages link to deeper OneDayMD and Cancer Advisor resources, creating a connected oncology information architecture.

Update-aware

High-impact pages should display publication and review/update dates when appropriate.

Human-readable first

Optimization should improve understanding rather than turning patient education into keyword-stuffed content.

Frequently asked questions

Cancer Academy FAQ

What is the OneDayMD Cancer Academy?
The OneDayMD Cancer Academy is a patient-first educational framework that organizes cancer information around diagnosis, biomarkers, treatment, response, resistance, monitoring and emerging research.
Is Cancer Academy medical advice?
No. Cancer Academy is educational content. It does not diagnose cancer, determine an individual's stage, prescribe treatment or replace consultation with qualified healthcare professionals.
Can Cancer Academy tell me which cancer treatment I should choose?
No. Treatment decisions depend on the individual's diagnosis, pathology, stage, biomarkers, medical history, treatment history, preferences and other clinical factors. Cancer Academy can help explain the concepts and questions involved.
Why are biomarkers important?
Some biomarkers can provide information that helps clinicians classify disease, estimate prognosis, monitor disease or determine whether a treatment may be appropriate. Their meaning depends on the cancer type and clinical context.
What does treatment resistance mean?
Treatment resistance means that cancer becomes less responsive or stops responding to a treatment. Mechanisms can include genetic changes, pathway adaptation, altered drug sensitivity, immune escape and changes in the tumor environment.
What is the E0–E5 evidence framework?
E0–E5 is Cancer Academy's educational framework for making evidence strength visible. It ranges from insufficient evidence through preliminary and preclinical evidence to stronger human evidence and established clinical standards.
Does Cancer Academy promote alternative cancer treatments?
Cancer Academy does not treat the terms "alternative" or "integrative" as evidence categories. Any intervention should be evaluated according to the quality of evidence supporting it, potential benefits, risks, interactions and its relationship to established cancer care.
Can I use Cancer Academy to prepare for an oncology appointment?
Yes. One of the Academy's main purposes is to help patients understand terminology and prepare informed questions for their healthcare team.
Where does Cancer Academy content come from?
Cancer Academy connects patient education with deeper OneDayMD and Cancer Advisor resources. Individual articles should identify their evidence sources, publication or update dates and relevant limitations.

Medical & safety disclaimer

Educational use only. The OneDayMD Cancer Academy provides general health and cancer information for educational purposes. It is not intended to diagnose, treat, cure or prevent any disease and does not constitute medical advice.

Cancer treatment is individualized. Decisions about surgery, radiation, chemotherapy, immunotherapy, targeted therapy, clinical trials, supportive care, supplements or any other intervention should be made with appropriately qualified healthcare professionals who know the patient's medical history and clinical circumstances.

Experimental, repurposed, complementary or integrative interventions should not be assumed to be effective simply because laboratory, observational or early clinical evidence exists. Evidence strength, safety, interactions, contraindications and regulatory status must be considered separately.

If you have symptoms that could represent a medical emergency, seek appropriate emergency medical care rather than relying on information on this website.

Your next step

Start with the question that matters most to you.

You do not need to understand all of oncology at once. Start with your cancer type, your test results or your current treatment question — then follow the evidence.

Start the Patient Journey Explore the Cancer Library

OneDayMD Cancer Academy — Patient-first cancer education, evidence navigation and oncology knowledge.

Part of the OneDayMD health information network.

Comments

Post a Comment